A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
Latest Information Update: 22 May 2025
At a glance
- Drugs Tigulixostat (Primary) ; Allopurinol
- Indications Gout; Hyperuricaemia
- Focus Registrational; Therapeutic Use
- Acronyms EURELIA2
- Sponsors LG Chem
Most Recent Events
- 15 May 2025 Status changed from recruiting to completed.
- 01 Apr 2025 Results presented in the Contemporary Clinical Trials.
- 22 May 2023 Status changed from not yet recruiting to recruiting.